GOALS OF THE WORK: To assess the relationship between oral mucositis (OM) and adverse clinical and economic outcomes in patients with hematologic malignancies receiving allogeneic hematopoietic stem-cell transplantation (HSCT). MATERIALS AND METHODS: A retrospective chart review study of 281 allogeneic HSCT recipients with hematologic malignancies was undertaken at a single academic center. OM extent and severity were assessed across eight oropharyngeal sites using a validated scale, which was scored as follows: no erythema/ulceration=0; erythema only=I; ulceration, one site=II; ulceration, two sites=III; ulceration, three sites=IV and ulceration, four or more sites=V. OM assessments began on the day of conditioning and continued twice weekly within 28 days or hospital discharge. Analyses examined the relationship between the worst OM grade and selected adverse outcomes, including days with fever, days of total parenteral nutrition (TPN), days of parenteral narcotic therapy, incidence of significant (common terminology criteria (CTC) grade 3 or 4) infection, mortality and inpatient days and charges. MAIN RESULTS: The mean age of the study subjects was 41 years. Of the patients, 96% (n = 269) received total body irradiation and 76% (n = 214) experienced an OM grade of > or =II (i.e., ulceration). The worst OM grade was significantly (p < 0.05) associated with the number of days of TPN and parenteral narcotic therapy, number of days with fever, incidence of significant infection, time in hospital and total inpatient charges. CONCLUSIONS: OM is associated with worse clinical and economic outcomes in patients with hematologic malignancies undergoing allogeneic HSCT.
GOALS OF THE WORK: To assess the relationship between oral mucositis (OM) and adverse clinical and economic outcomes in patients with hematologic malignancies receiving allogeneic hematopoietic stem-cell transplantation (HSCT). MATERIALS AND METHODS: A retrospective chart review study of 281 allogeneic HSCT recipients with hematologic malignancies was undertaken at a single academic center. OM extent and severity were assessed across eight oropharyngeal sites using a validated scale, which was scored as follows: no erythema/ulceration=0; erythema only=I; ulceration, one site=II; ulceration, two sites=III; ulceration, three sites=IV and ulceration, four or more sites=V. OM assessments began on the day of conditioning and continued twice weekly within 28 days or hospital discharge. Analyses examined the relationship between the worst OM grade and selected adverse outcomes, including days with fever, days of total parenteral nutrition (TPN), days of parenteral narcotic therapy, incidence of significant (common terminology criteria (CTC) grade 3 or 4) infection, mortality and inpatient days and charges. MAIN RESULTS: The mean age of the study subjects was 41 years. Of the patients, 96% (n = 269) received total body irradiation and 76% (n = 214) experienced an OM grade of > or =II (i.e., ulceration). The worst OM grade was significantly (p < 0.05) associated with the number of days of TPN and parenteral narcotic therapy, number of days with fever, incidence of significant infection, time in hospital and total inpatient charges. CONCLUSIONS: OM is associated with worse clinical and economic outcomes in patients with hematologic malignancies undergoing allogeneic HSCT.
Authors: S T Sonis; G Oster; H Fuchs; L Bellm; W Z Bradford; J Edelsberg; V Hayden; J Eilers; J B Epstein; F G LeVeque; C Miller; D E Peterson; M M Schubert; F K Spijkervet; M Horowitz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Corey Cutler; Shuli Li; Haesook T Kim; Patricia Laglenne; Kwok Chuen Szeto; Laura Hoffmeister; M Joel Harrison; Vincent Ho; Edwin Alyea; Stephanie J Lee; Robert Soiffer; Stephen Sonis; Joseph H Antin Journal: Biol Blood Marrow Transplant Date: 2005-05 Impact factor: 5.742
Authors: A M Wardley; G C Jayson; R Swindell; G R Morgenstern; J Chang; R Bloor; C J Fraser; J H Scarffe Journal: Br J Haematol Date: 2000-08 Impact factor: 6.998
Authors: A P Rapoport; L F Miller Watelet; T Linder; S Eberly; R F Raubertas; J Lipp; R Duerst; C N Abboud; L Constine; J Andrews; M A Etter; L Spear; E Powley; C H Packman; J M Rowe; U Schwertschlag; C Bedrosian; J L Liesveld Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Linda S Elting; Catherine Cooksley; Mark Chambers; Scott B Cantor; Ellen Manzullo; Edward B Rubenstein Journal: Cancer Date: 2003-10-01 Impact factor: 6.860
Authors: Kim Robien; Mark M Schubert; Barbara Bruemmer; Michele E Lloid; John D Potter; Cornelia M Ulrich Journal: J Clin Oncol Date: 2004-04-01 Impact factor: 44.544
Authors: W Y K Hwang; L-P Koh; H J Ng; P H C Tan; C T H Chuah; S C Fook; H Chow; K W Tan; C Wong; C H Tan; Y-T Goh Journal: Bone Marrow Transplant Date: 2004-07 Impact factor: 5.483
Authors: Jeevendra Kanagalingam; Mohamed Ibrahim A Wahid; Jin-Ching Lin; Nonette A Cupino; Edward Liu; Jin-Hyoung Kang; Shouki Bazarbashi; Nicole Bender Moreira; Harsha Arumugam; Stefan Mueller; Hanlim Moon Journal: Support Care Cancer Date: 2018-01-31 Impact factor: 3.603
Authors: Walter J F M van der Velden; Thijs M P van Iersel; Nicole M A Blijlevens; J Peter Donnelly Journal: BMC Med Date: 2009-09-08 Impact factor: 8.775